ATE298236T1 - Bestimmte glycin-derivate als faktor xa inhibitoren zur verwendung in der behandlung von thrombose - Google Patents

Bestimmte glycin-derivate als faktor xa inhibitoren zur verwendung in der behandlung von thrombose

Info

Publication number
ATE298236T1
ATE298236T1 AT02791222T AT02791222T ATE298236T1 AT E298236 T1 ATE298236 T1 AT E298236T1 AT 02791222 T AT02791222 T AT 02791222T AT 02791222 T AT02791222 T AT 02791222T AT E298236 T1 ATE298236 T1 AT E298236T1
Authority
AT
Austria
Prior art keywords
factor
treatment
inhibitors
thrombosis
sup
Prior art date
Application number
AT02791222T
Other languages
English (en)
Inventor
Michael Robert Wiley
Daniel Jon Sall
Christopher William Murray
Stephen Clinton Young
Jolie Anne Bastian
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of ATE298236T1 publication Critical patent/ATE298236T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56Nitrogen atoms
    • C07D211/58Nitrogen atoms attached in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT02791222T 2001-12-12 2002-12-09 Bestimmte glycin-derivate als faktor xa inhibitoren zur verwendung in der behandlung von thrombose ATE298236T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33932601P 2001-12-12 2001-12-12
PCT/US2002/036150 WO2003049735A1 (en) 2001-12-12 2002-12-09 Certain glycine derivatives as factor xa inhibitors for use in the treatment of thrombotic disorders

Publications (1)

Publication Number Publication Date
ATE298236T1 true ATE298236T1 (de) 2005-07-15

Family

ID=23328487

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02791222T ATE298236T1 (de) 2001-12-12 2002-12-09 Bestimmte glycin-derivate als faktor xa inhibitoren zur verwendung in der behandlung von thrombose

Country Status (7)

Country Link
US (2) US7078415B2 (de)
EP (1) EP1455787B1 (de)
AT (1) ATE298236T1 (de)
AU (1) AU2002366563A1 (de)
DE (1) DE60204800T2 (de)
ES (1) ES2242086T3 (de)
WO (1) WO2003049735A1 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7169795B2 (en) 2003-09-30 2007-01-30 Bristol Myers Squibb Company Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1009758B1 (de) 1997-08-29 2005-06-01 Tularik Limited Meta-benzamidinderivate als serinprotease-inhibitoren
WO2000071507A2 (en) 1999-05-24 2000-11-30 Cor Therapeutics, Inc. INHIBITORS OF FACTOR Xa
DE60022508T2 (de) 1999-06-14 2006-06-08 Eli Lilly And Co., Indianapolis Inhibitoren von serin proteasen
US6521609B1 (en) * 1999-08-10 2003-02-18 Boehringer Ingelheim Pharma Kg Use of CGRP antagonists and CGRP release inhibitors for combating menopausal hot flushes
GB0030305D0 (en) * 2000-12-13 2001-01-24 Lilly Co Eli Compounds
GB0030304D0 (en) 2000-12-13 2001-01-24 Lilly Co Eli Compounds
EP1409479B1 (de) 2001-07-26 2008-01-23 Eli Lilly And Company 1-glycinyl-4-(1-methylpiperidin-4-yl)piperazine und -piperidine als faktor-xa-antagonisten
WO2003050109A1 (en) 2001-12-12 2003-06-19 Eli Lilly And Company Alanyl-piperidine heterocyclic derivatives useful against cardiovascular diseases

Also Published As

Publication number Publication date
US7297706B2 (en) 2007-11-20
US7078415B2 (en) 2006-07-18
DE60204800T2 (de) 2006-05-04
ES2242086T3 (es) 2005-11-01
AU2002366563A1 (en) 2003-06-23
US20070072869A1 (en) 2007-03-29
WO2003049735A1 (en) 2003-06-19
EP1455787B1 (de) 2005-06-22
EP1455787A1 (de) 2004-09-15
US20040249155A1 (en) 2004-12-09
DE60204800D1 (de) 2005-07-28

Similar Documents

Publication Publication Date Title
CY1105386T1 (el) Βενζοϋλοσουλφοναμιδια και σουλφονυλβενζαμιδινες για χρηση σαν παραγοντες κατα του ογκου
DE60127863D1 (de) Phenylderivate
DE60310576D1 (en) 2-hydroxy-6-phenylphenanthridine als pde-4-hemmer
DE602004017736D1 (de) Verwendung von rapamycin und dessen derivaten zur behandlung von knochenverlust
DE60236600D1 (de) Substituierte 1h-dihydropyrazole, ihre herstellung und verwendung
ATE311363T1 (de) Sulfohydroxamsäure and sulfohydroxamate und ihre verwendung als mek-inhibitoren
ATE521353T1 (de) Neues trisubstitutiertes 8h-pyridoä2,3- düpyrimidin-7-onderivat zur behandlung von durch csbp/p38kinase vermittelten krankheiten
ATE413388T1 (de) Muskarin antagonisten
DE69928655D1 (de) Substituierte porphyrine
EA200301100A1 (ru) Новые фталазиноны
DE60206164D1 (de) Trisubstituierte-n-((1s)-1,2,3,4-tetrahydro-1-naphthalenyl) benzamide welche p2x3 und p2x2/3 enthaltende rezeptoren inhibieren
DE60221505D1 (de) FAKTOR Xa BENZAMIDIN INHIBITOREN
DE50208918D1 (de) 6-aminomorphinanderivate, herstellungsverfahren dafür und deren verwendung
MY141011A (en) Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones
ATE302002T1 (de) Verwendung von pyrazolderivaten zur behandlung von unfruchtbarkeit
DE602004017332D1 (de) Neue kondensierte n-pyrazinyl-sulfonamide und deren verwendung bei der behandlung von chemokinvermittelten krankheiten
DE60129829D1 (de) Zyklisierte benzamid-neurokinin-antagonisten zur verwendung in therapie
ATE359283T1 (de) Substituierte pyrazinonverbindungen zur behandlung von entzündungen
MXPA03007413A (es) Composicion y metodo para tratar enfermedades inflamatorias.
CY1105345T1 (el) Φαινυλαλκινια
ATE386525T1 (de) 3-substituierte 6,7- dihydroxytetrahydroisochinolin-derivate zur verwendung als antibkaterielle mittel
ATE287403T1 (de) 6-phenylbenzonaphthyidine
DE50205466D1 (de) Substituierte 2,5-diamidoindole als ece-inhibitoren zur behandlung von kardiovaskulären erkrankungen
DE60213365D1 (de) Verwendung von mglur5 antagonisten zur behandlung von pruritischen zuständen
DE60224805D1 (de) 1-glycinyl-4-(1-methylpiperidin-4-yl)piperazine un

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties